AUR-AFKB-TTP1-A-10-0-R-A741-41
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.210
- PROTEIN_SECRETION+0.190
- PANCREAS_BETA_CELLS+0.160
- ESTROGEN_RESPONSE_EARLY+0.130
- ANDROGEN_RESPONSE+0.090
- TGF_BETA_SIGNALING+0.050
- TNFA_SIGNALING_VIA_NFKB+0.050
- HEDGEHOG_SIGNALING-0.040
- HEME_METABOLISM-0.040
- NOTCH_SIGNALING-0.040
Top 10 suppressed
- MYC_TARGETS_V2-0.620
- OXIDATIVE_PHOSPHORYLATION-0.520
- E2F_TARGETS-0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.490
- MYC_TARGETS_V1-0.460
- ADIPOGENESIS-0.410
- MTORC1_SIGNALING-0.410
- G2M_CHECKPOINT-0.380
- CHOLESTEROL_HOMEOSTASIS-0.370
- GLYCOLYSIS-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A26E-01B-06R-A277-07 | — | D | 0.907 |
| 2 | AUR-AFUN-TTP1-A-1-0-R-A741-41 | — | D | 0.906 |
| 3 | TCGA-A7-A0DB-01C-02R-A277-07 | — | D | 0.896 |
| 4 | AUR-AER8-TTP1-A-1-0-R-A741-41 | — | D | 0.893 |
| 5 | d1447a31-64bb-4e70-ae50-eeff7a605f38 | — | — | 0.887 |
| 6 | dab9a230-f4f6-4692-863a-5fdcf516be24 | — | — | 0.887 |
| 7 | MBCProject_0771_T1_RNA | — | A | 0.885 |
| 8 | 69550f7f-5251-4657-863b-bd35d69c82c4 | — | — | 0.883 |
| 9 | TCGA-CV-7446-01A-11R-2232-07 | — | — | 0.882 |
| 10 | TCGA-E2-A15I-01A-21R-A137-07 | — | B | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.050 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.050 | Inavolisib | — uncovered |